

Edgar Filing: GENOME THERAPEUTICS CORP - Form 10-K/A

GENOME THERAPEUTICS CORP

Form 10-K/A

November 12, 2002

=====

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-K/A
(Amendment No. 2)

(MARK ONE)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the fiscal year ended: December 31, 2001

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

Commission file number: 0-10824

Genome Therapeutics Corp.
(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction of incorporation or
organization)

04-2297484
(IRS employer identification number)

100 Beaver Street, Waltham, Massachusetts
(Address of principal executive offices)

02453
(Zip Code)

Registrant's telephone number: (781) 398-2300

Securities registered pursuant to Section 12(b) of the Act: NONE

Securities registered pursuant to Section 12(g) of the Act:
COMMON STOCK, \$.10 PAR VALUE
(Title of Class)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. ☒

Edgar Filing: GENOME THERAPEUTICS CORP - Form 10-K/A

The aggregate market value of the voting stock held by non-affiliates of the registrant as of November 8, 2002 was approximately \$37,795,944.

The number of shares outstanding of the registrant's common stock as of November 8, 2002 was 23,066,072.

Documents Incorporated By Reference

Portions of the registrant's proxy statement for use at its Annual Meeting to be held on June 19, 2002 are incorporated by reference into Part III.

=====

Introductory Note

This Annual Report on Form 10-K/A replaces Exhibit 10.61 of Form 10-K filed on April 1, 2002.

1

PART IV

ITEM 14. Exhibits, Financial Statement Schedules and Reports on Form 8K

(a) FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES (1) AND (2) See "Index to Consolidated Financial Statements and Financial Statement Schedules" appearing on page F-1.

(3) Exhibits

Exhibit No.	Description
3	Restated Articles of Organization and By-laws/(1)/
3.1	Amendment dated January 5, 1982 to Restated Articles of Organization/(2)/
3.2	Amendment dated January 24, 1983 to Restated Articles of Organization/(3)/
3.3	Amendment dated January 17, 1984 to Restated Articles of Organization/(4)/
3.4	Amendment dated October 20, 1987 to the By-laws/(8)/
3.5	Amendment dated December 9, 1987 to Restated Articles of Organization/(9)/
3.6	Amendment dated October 16, 1989 to the By-law/(11)/
3.7	Amendment dated January 24, 1994 to Articles Restated Articles of Organization/(14)/
3.8	Amendment dated August 31, 1994 to Restated Articles of Organization/(14)/
3.9	Amendment dated March 15, 2001 to Restated Articles of Organization/(33)/
3.10	By-Laws of Genome Therapeutics Corp (as amended through July 24, 2001)/(34)/
4.2	Form of Note dated March 5, 2002 received by Smithfield Fiduciary LLC and the Tail Wind Fund, Ltd./(35)/
4.3	Form of Warrant received by Smithfield Fiduciary LLC and The Tail Wind Fund, Ltd./(35)/
10.4	Incentive Stock Option Plan and Form of Stock Option Certificate/(1)/

Edgar Filing: GENOME THERAPEUTICS CORP - Form 10-K/A

- 10.6 Genome Therapeutics Corp. (f/k/a Collaborative Research) Incentive Savings Plan/(6)/
- 10.7 Amendment dated November 4, 1986 to the Genome Therapeutics Corp. (f/k/a Collaborative Research) Incentive Savings Plan dated March 1, 1985/(7)/
- 10.14 1991 Stock Option Plan and Form of Stock Option Certificate/(12)/
- 10.15 Lease dated November 17, 1992 relating to certain property in Waltham, Massachusetts/(13)/
- 10.16 Lease dated June 3, 1993 relating to certain property in Waltham, Massachusetts/(13)/
- 10.19 Employment Agreement with Robert J. Hennessey/(13)/
- 10.22 Lease Amendment dated August 1, 1994 relating to certain property in Waltham, MA/(14)/
- 10.24 1993 Stock Option Plan and Form of Stock Option Certificate/(14)/
- 10.28 Agreement between the Company and AstraZeneca PLC (f/k/a Astra Hassle AB) dated August 31, 1995/(16)/*
- 10.29 Collaboration and License Agreement between the Company, Schering Corporation and Schering-Plough Ltd., dated as of December 6, 1995/(18)/*
- 10.30 Form of director Stock Option Agreement and schedule of director options granted/(17)/

1

Exhibit No.	Description
-----	-----
10.37	Lease amendment dated November 15, 1996 to certain property in Waltham, MA/(19)/
10.38	Collaboration and License Agreement between the Company, Schering Corporation and Schering-Plough Ltd., dated as of December 20, 1996/(20)/*
10.39	Credit agreement between the Company and Fleet National Bank dated February 28, 1997/(21)/
10.40	Credit agreement between the Company and U S Trust (f/k/a Sumitomo Bank, Limited) dated July 31, 1997/(22)/
10.41	Collaboration and License Agreement between the Company and Schering Corporation, dated September 22, 1997/(23)/*
10.42	Collaboration and License Agreement between the Company and Schering-Plough Ltd. dated September 22, 1997/(23)/*
10.43	Credit modification agreement between the Company and Fleet National Bank, dated March 9, 1998/(24)/
10.44	1997 Directors' Deferred Stock Plan/(25)/
10.45	1997 Stock Option Plan/(25)/
10.46	Amended Employment Agreement with Robert J. Hennessey/(26)/
10.47	Collaboration and License Agreement between the Company and American Home Products, Inc., acting through its Wyeth-Ayerst Division, dated December 20, 1999/(27)/
10.49	Collaboration and License Agreement between Genome Therapeutics Corporation and bioMerieux Incorporated dated as of September 30, 1999/(29)/
10.50	Registration Rights Agreement between the Company and bioMerieux Alliance sa dated September 30, 1999/(30)/
10.51	Compound Discovery Collaboration Agreement, dated October 17, 2000 between the Company and ArQule, Inc./(31)/*
10.52	2001 Incentive Plan/(32)/
10.53	Stock Option Agreements with Steven M. Rauscher/(32)/
10.55	Employment Letter with Steven M. Rauscher/(34)/
10.56	Employment Letter with Stephen Cohen/(34)/

Edgar Filing: GENOME THERAPEUTICS CORP - Form 10-K/A

10.57 Employment Letter with Richard Labaudinere PhD/(34)/
 10.58 Purchase Agreement dated March 5, 2002 among Smithfield Fiduciary LLC,
 The Tail Wind Fund, Ltd. and the Company/(35)/
 10.59 Registration Rights Agreement dated March 5, 2002 among Smithfield
 Fiduciary LLC, The Tail Wind Fund, Ltd. and the Company/(35)/
 10.60 Employment Letter with Robert J. Hennessey/(36)/
 10.61 License and Supply Agreement between the Company and Biosearch Italia,
 S.P.A., dated October 8, 2001/(38)/
 23. Consent of Arthur Andersen LLP Independent Public Accounts/(37)/
 99.1 Risk Factors/(36)/
 99.2 Letter to Commission Pursuant to Temporary Note 3T/(37)/

* Confidential treatment requested with respect to a portion of this Exhibit.

/(1)/ Filed as exhibits to the Company's Registration Statement on Form S-1
 (No. 2-75230) and incorporated herein by reference.
 /(2)/ Filed as an exhibit to the Company's Quarterly Report on Form 10-Q for
 the quarter ended February 27, 1982 and incorporated herein by
 reference.
 /(3)/ Filed as exhibits to the Company's Quarterly Report on Form 10-Q for the
 quarter ended February 26, 1983 and incorporated herein by reference.
 /(4)/ Filed as an exhibit to the Company's Quarterly Report on Form 10-Q for
 the quarter ended February 25, 1984 and incorporated herein by
 reference.
 /(6)/ Filed as an exhibit to the Company's Annual Report on Form 10-K for the
 fiscal year ended August 31, 1985 and incorporated herein by reference.
 /(7)/ Filed as exhibits to the Company's Annual Report on Form 10-K for the
 fiscal year ended August 31, 1986 and incorporated herein by reference.

2

/(8)/ Filed as an exhibit to the Company's Annual Report on Form 10-K for
 the year ended August 31, 1987 and incorporated herein by reference.
 /(9)/ Filed as an exhibit to the Company's Quarterly Report on Form 10-Q for
 the quarter ended November 28, 1987 and incorporated herein by
 reference.
 /(11)/ Filed as an exhibit to the Company's Annual Report on Form 10-K for
 the fiscal year ended August 31, 1989 and incorporated herein by
 reference.
 /(12)/ Filed as an exhibit to the Company's Annual Report on Form 10-K for
 the fiscal year ended August 31, 1992 and incorporated herein by
 reference.
 /(13)/ Filed as exhibits to the Company's Annual Report on Form 10-K for the
 fiscal year ended August 31, 1993 and incorporated herein by
 reference.
 /(14)/ Filed as exhibits of the Company's Annual Report on Form 10-K for the
 fiscal year ended August 31, 1994 and incorporated herein by
 reference.
 /(16)/ Filed as an exhibit to the Company's Annual Report on Form 10-K/A3 for
 the year ended August 31, 1995 and incorporated herein by reference.
 /(17)/ Filed as an exhibit to the Company Registration Statement on Forms S-8
 (File No. 33-61191) and incorporated herein by reference.
 /(18)/ Filed as an exhibit to the Company's Quarterly Report on Form 10-Q for
 the quarter ended November 25, 1995 and incorporated herein by
 reference.
 /(19)/ Filed as an exhibit to the Company's 10-K for fiscal year ended August
 31, 1996 and incorporated herein by reference.
 /(20)/ Filed as an exhibit to the Company's 10-Q/A for the quarter ended

Edgar Filing: GENOME THERAPEUTICS CORP - Form 10-K/A

March 1, 1997 and incorporated herein by reference.

/(21)/ Filed as an exhibit to the Company's 10-Q for the quarter ended May 31, 1997 and incorporated herein by reference.

/(22)/ Filed as an exhibit to the Company's 10-K for fiscal year ended August 31, 1997 and incorporated herein by reference.

/(23)/ Filed as exhibits to the Company's 10-Q for the quarter ended February 28, 1998 and incorporated herein by reference.

/(24)/ Filed as an exhibit to the Company's 10-Q for the quarter ended May 30, 1998 and incorporated herein by reference.

/(25)/ Filed as exhibits to the Company's Registration Statement on Forms S-8 (333-49069) and incorporated herein by reference.

/(26)/ Filed as an exhibit to the Company's 10-K for the fiscal year ended August 31, 1998 and incorporated herein by reference.

/(27)/ Filed as an exhibit to the Company's 8-K filed on March 8, 2000 and incorporated herein by reference.

/(29)/ Filed as an exhibit to the Company's 10-Q for the quarter ended November 27, 1999 and incorporated herein by reference.

/(30)/ Filed as an exhibit to the Company's Registration Statement on Forms S-3 (333-32614) and incorporated herein by reference.

/(31)/ Filed as an exhibit to the Company's 10-K for the quarter ended November 25, 2000 and incorporated herein by reference.

/(32)/ Filed as an exhibit to the Company's Registration Statement on Form S-8 (333-58274) and incorporated herein by reference./ (31)/

/(33)/ Filed as an exhibit to the Company's 10-Q for the quarter ended February 24, 2001 and incorporated herein by reference.

/(34)/ Filed as an exhibit to the Company's 10-Q for the quarter ended September 29, 2001 and incorporated herein by reference.

/(35)/ Filed as an exhibit to the Company's 8-K filed on March 6, 2002 and incorporated herein by reference.

/(36)/ Filed as an exhibit to the Company's 10-K for the fiscal year ended December 31, 2001 and incorporated herein by reference.

/(37)/ Filed as an exhibit to the Company's Annual Report on Form 10-K/A1 for the fiscal year ended December 31, 2001 and incorporated herein by reference.

/(38)/ Filed herewith.

3

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Genome Therapeutics Corp. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 12, 2002.

GENOME THERAPEUTICS CORP.

/S/ STEPHEN COHEN

Stephen Cohen
Senior Vice President and Chief
Financial Officer